Platelet glycoprotein receptor VI in abdominal aortic aneurysms, TP53 mutations in 5q-deleted myelodysplastic syndrome, and immunostimulatory cytokine plus CAR T-cell therapy in acute lymphoblastic leukemia

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

710: That New Mouse Pad Feeling 2h 13m · 24 Sep 2026 · Accidental Tech Podcast

Steven Bartlett REVEALS the Secret Behind the World’s Fastest Growing Podcast | PBD Podcast #861 1h 27m · 24 Sep 2026 · PBD Podcast

1PM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

Tucker Carlson on his MAGA split and Trump's 'nihilism' | NPR's Newsmakers 58 min · 24 Sep 2026 · Up First from NPR

#2558 - Tyler Engle 2h 23m · 24 Sep 2026 · The Joe Rogan Experience

TELL ME SOMETHING GOOD (THURS) Amy Avoided Murder! + Which Show Member Got An Office? 43 min · 24 Sep 2026 · The Bobby Bones Show

Report any issue

Source

Recorded17 Oct 2024

Publisherfeeds.transistor.fm ↗

Handlerec:11741945

Show notes

In this week's episode, we'll learn about the role of a platelet-specific glycoprotein receptor in abdominal aortic aneurysm formation, the influence of TP53 mutations on outcomes for patients with 5q-deleted myelodysplastic syndrome, and a rational combination treatment intended to produce more durable responses in patients with refractory B-cell acute lymphoblastic leukemia who are treated with CAR T-cell therapy.Featured Articles:Soluble glycoprotein VI predicts abdominal aortic aneurysm growth rate and is a novel therapeutic targetInfluence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletionA phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in